Ariceum Therapeutics
Liam Rayman is a skilled professional in the biomedical field with experience in various roles, including BTA at Ariceum Therapeutics and Archivist at recordsale & musicberlin GmbH. Liam has contributed to research at the Max Delbrück Center, focusing on nucleotide pool depletion in neuroblastoma cells, and has developed expertise in nucleotide extraction, mass spectrometry, and data analysis. Previous roles include Student Employee at Berlin Heart GmbH, QA Analyst and Customer Service Advisor at ZAGENO Inc., and Medical Scientist at University Hospital Waterford. Academic credentials include a Master's degree in Molecular Medicine from Charité - Universitätsmedizin Berlin and multiple degrees in Biomedical Science and Clinical Laboratory Practice.
This person is not in any teams
Ariceum Therapeutics
1 followers
Ariceum Therapeutics is a privately held radiopharmaceutical firm in the clinical stage that specializes in the detection and targeted treatment of aggressive malignancies, such as neuroendocrine and other hard-to-treat cancers.177Lu-satoreotide tetraxetan (Satoreotide), the company's primary targeted systemic radiopharmaceutical therapy, isan antagonist of the somatostatin type 2 receptor (SSTR2), which is overexpressed in many neuroendocrine tumors. For the simultaneous diagnosis and targeted radionuclide treatment of neuroendocrine malignancies, some aggressive tumors, and childhood cancer, which currently offers few treatment choices and a poor prognosis, we are developing satoreotide as a "theranostic" pair.